Trial
NCT02119676
Study of Ruxolitinib in Colorectal Cancer Patients
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
CRC (Colorectal Cancer)
Intervention
Ruxolitinib
Why stopped
Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-13